Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group

被引:115
作者
Bajetta, E
Buzzoni, R
Mariani, L
Beretta, E
Bozzetti, F
Bordogna, G
Aitini, E
Fava, S
Schieppati, G
Pinotti, G
Visini, M
Ianniello, G
Di Bartolomeo, M
机构
[1] Ist Nazl Studio & Cura Tumori, Med Oncol Unit B, I-20133 Milan, Italy
[2] Ist Nazl Studio & Cura Tumori, Stat & Biometry Unit, I-20133 Milan, Italy
[3] Ist Nazl Studio & Cura Tumori, Surg Oncol Unit, I-20133 Milan, Italy
[4] Ist Sci Biomed S Raffaele, Milan, Italy
[5] C Poma Gen Hosp, Mantua, Italy
[6] Gen Hosp, Legnano, Italy
[7] Gen Hosp, Saronno, Italy
[8] Gen Hosp, Varese, Italy
[9] Gen Hosp, Lecce, Italy
[10] G Rummo Gen Hosp, Benevento, Italy
关键词
adjuvant chemotherapy; gastric cancer; polychemotherapy;
D O I
10.1093/annonc/mdf040
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The aim of this study was to determine the efficacy of the EAP regimen (etoposide, adriamycin and cisplatin) followed by the Machover schedule (fluorouracil and folinic acid) given as adjuvant treatment to patients with poor prognostic factors (N+ or T3/4). Patients and methods: Before randomisation, the subjects were stratified on the basis of node involvement (N+ or N-) and the time from surgery to randomisation (less than or equal to21 days or >22 days). The surgical procedures for sub-total or total gastrectomy with D2 dissection were standardised among the participating centres. Results: Between December 1992 and December 1997, 274 patients were enrolled: 137 in the treatment arm and 137 in the control arm. The majority of the patients (90%) were N+. After a median follow up of 66 months (range 2-83), the 5-year overall survival (OS) was 52% in the treatment arm and 48% in the control arm [hazard ratio (HR) 0.93; 95% confidence interval (CI) 0.65-1.34]; the 5-year disease-free survival (DFS) was 49% and 44%, respectively (HR: 0.83; 95% CI 0.59-1.17). Among the patients with N-/N+ (1-6), the 5-year OS was 61% in the treatment group and 60% in the control group, in those with N+ (1-6), it was 42% and 22%. The treatment was completed by 87% of patients. Drug-related grade 3/4 WHO toxicities included leukopenia (21%), nausea and vomiting (14%), mucositis (9%), neutropenia (3%) and thrombocytopenia (2%). There were two deaths due to sepsis, Conclusions: Although our results are not statistically significant, there was a limited relative risk reduction in the patients receiving adjuvant therapy (17% in DFS and 7% in OS). The data suggest that D2 surgery may have a favourable impact on OS.
引用
收藏
页码:299 / 307
页数:9
相关论文
共 33 条
[21]   Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: A meta-analysis of published randomised trials - A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente) [J].
Mari, E ;
Floriani, I ;
Tinazzi, A ;
Buda, A ;
Belfiglio, M ;
Valentini, M ;
Cascinu, S ;
Barni, S ;
Labianca, R ;
Torri, V .
ANNALS OF ONCOLOGY, 2000, 11 (07) :837-843
[22]  
MULLER G, 1985, CHIRURG, V56, P539
[23]   Randomized trial of adjuvant chemotherapy versus central after curative resection for gastric cancer: 5-year follow-up [J].
Neri, B ;
Cini, G ;
Andreoli, F ;
Boffi, B ;
Francesconi, D ;
Mazzanti, R ;
Medi, F ;
Mercatelli, A ;
Romano, S ;
Siliani, L ;
Tarquini, R ;
Moretti, R .
BRITISH JOURNAL OF CANCER, 2001, 84 (07) :878-880
[24]   Global cancer statistics [J].
Parkin, DM ;
Pisani, P ;
Ferlay, J .
CA-A CANCER JOURNAL FOR CLINICIANS, 1999, 49 (01) :33-64
[25]   PHASE-II STUDY WITH THE COMBINATION ETOPOSIDE, DOXORUBICIN, AND CISPLATIN IN ADVANCED MEASURABLE GASTRIC-CANCER [J].
PREUSSER, P ;
WILKE, H ;
ACHTERRATH, W ;
FINK, U ;
LENAZ, L ;
HEINICKE, A ;
MEYER, J ;
MEYER, HJ ;
BUENTE, H .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (09) :1310-1317
[26]  
Roder JD, 1998, CANCER-AM CANCER SOC, V82, P621, DOI 10.1002/(SICI)1097-0142(19980215)82:4<621::AID-CNCR2>3.3.CO
[27]  
2-2
[28]  
*SAS I INC, 1990, SAS STAT TM US GUID, V1
[29]  
*SAS I INC, 1990, SAS STAT TM US GUID, V2
[30]  
Shimada K, 1999, CANCER-AM CANCER SOC, V86, P1657, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1657::AID-CNCR6>3.0.CO